HDM Labs Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: HDM Labs Inc Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

HDM Labs Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

HDM Labs Inc

Pharmaceutical Importer · United States · Medical Devices & Diagnostics Focus · $1.1M Total Trade · DGFT Verified

HDM Labs Inc is a pharmaceutical importer based in United States with a total trade value of $1.1M across 2 products in 1 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. HDM Labs Inc sources from 2 verified Indian suppliers, with Advy Chemical Private Limited accounting for 100.0% of imports.

HDM Labs Inc — Import Portfolio & Supplier Network

HDM Labs Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to HDM Labs Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Advy Chemical Private Limited	$519.1K	26	100.0%
Yashraj Biotechnology Limited	$1	1	0.0%

HDM Labs Inc sources from 2 verified Indian suppliers across .

What Formulations Does HDM Labs Inc Import?

Formulation	Value	Ships
Diagnostic reagents human igg fc	$200.0K	6
Human igg fc affinity purified goat	$100.0K	5
Alpha-feto	$76.3K	2
Diagnostic reagents human igg fc	$50.0K	2
Diagnostic reagents human igg fc affinity purified goat	$50.0K	2
Alpha-feto protein 284.10 ML x 2 bottles(packed in 500 ML bottle)	$42.1K	1
Hepatitis b surface antigen subtype ad (ultra pure)	$782	1
Hepatitis b surface antigen (hbsag)-ay batch # rmhby0001/24 (166 ML=1nos) laboratory raw material to be used to make	$1	1
Pregnancy associated plasma protein a (papp-a)	$0	1
Diagnostic reagents hepatitis b surfaceantigen subtype concentrate	$0	1
Alpha-feto protein 2.85 ML x 1 vial (packed in 5 ML vial)	$0	1
Hepatitis b surface antigen subtype ay (ultra pure)	$0	1
Pregnancy associated plasma protein a papp a	$0	1
Hepatitis b surface antigen subtype ad ultra	$0	1
Hepatitis b surface antigen subtype ay ultra	$0	1

HDM Labs Inc imports 15 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diagnostic	Medical Devices & Diagnostics	$550.0K	11	3.0%	3
2	Reagent	Medical Devices & Diagnostics	$550.0K	11	4.2%	2

HDM Labs Inc imports 2 pharmaceutical products across 1 categories into United States totaling $1.1M.

HDM Labs Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

HDM Labs Inc, established in 1988, is a U.S.-based pharmaceutical importer specializing in the distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered at 153 Kingston Blvd., Island Park, New York 11558, the company operates as a specialty distributor, focusing on high-quality medical diagnostic services and pharmaceutical products. Their product portfolio encompasses human proteins, high-quality grade plasma, and various generic pharmaceutical products. HDM Labs Inc is recognized for its commitment to meeting global safety standards and providing value-driven solutions to its clientele.

2Distribution Network

HDM Labs Inc's distribution network is primarily centered in the United States, with its main office located in Island Park, New York. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's focus on high-quality grade plasma and human proteins suggests a robust infrastructure capable of handling sensitive medical products. The emphasis on globally accepted safety standards indicates that their distribution processes are designed to ensure product integrity and compliance with international regulations.

3Industry Role

In the U.S. pharmaceutical supply chain, HDM Labs Inc functions as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company plays a crucial role in enhancing the availability of essential medical products within the U.S. market. Their focus on high-quality diagnostic services and pharmaceutical products positions them as a key player in meeting the diverse needs of healthcare providers and patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — HDM Labs Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

HDM Labs Inc's sourcing strategy exhibits a high degree of concentration, with a significant portion of their imports originating from a single supplier, ADVY CHEMICAL PRIVATE LIMITED. This supplier has been responsible for 26 shipments totaling $519,000, accounting for 100% of the company's imports from India. Such dependency on a single supplier can pose risks related to supply chain disruptions, quality control, and pricing negotiations. However, the consistent volume of imports from ADVY CHEMICAL PRIVATE LIMITED suggests a stable and reliable relationship, which may mitigate some of these risks. The minimal involvement of other suppliers indicates limited diversification in sourcing, which could be a strategic choice to maintain quality consistency or a result of limited supplier options for specific product categories.

2Supply Chain Resilience

The resilience of HDM Labs Inc's supply chain is closely tied to the stability and reliability of ADVY CHEMICAL PRIVATE LIMITED. The company's exclusive sourcing from this supplier suggests a deep integration and trust in their manufacturing capabilities. However, the lack of backup suppliers introduces potential vulnerabilities, such as exposure to geopolitical risks, natural disasters, or operational challenges in India. The limited diversification in formulations—importing only 15 unique formulations—further concentrates risk. To enhance supply chain resilience, HDM Labs Inc may consider diversifying its supplier base and expanding its product portfolio to mitigate potential disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all imported drugs meet the same standards for quality, safety, and effectiveness as those manufactured domestically. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, including requirements for drug approval, labeling, and manufacturing practices. For Indian pharmaceutical products, the FDA requires that manufacturers comply with its regulations, which may involve inspections and certifications to confirm adherence to U.S. standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Importers must ensure that their products are manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards recognized by the FDA. While the FDA does not have a specific list of approved GMP certifications, it generally accepts certifications from reputable organizations such as the European Union's GMP, World Health Organization's GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must also obtain a Drug Establishment Registration number and a Drug Listing Number for each product, facilitating the FDA's review and approval process.

HDM Labs Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

HDM Labs Inc's focus on importing diagnostic products and reagents aligns with the growing demand for medical devices and diagnostic tools in the U.S. market. The substantial investment in these categories, totaling $1.1 million, indicates a strategic emphasis on providing essential diagnostic solutions to healthcare providers. The choice to import from India suggests a focus on cost-effective sourcing while maintaining product quality. This strategy positions HDM Labs Inc to meet the increasing needs of the U.S. healthcare system for reliable and affordable diagnostic products.

2Sourcing Profile

HDM Labs Inc's sourcing strategy is characterized by a strong reliance on a single supplier, ADVY CHEMICAL PRIVATE LIMITED, for its imports from India. This approach may be driven by the supplier's ability to meet the company's quality standards and product specifications. The limited diversification in sourcing could be a strategic choice to ensure consistency and reliability in product offerings. However, this concentration also exposes the company to potential risks associated with supply chain disruptions and limited flexibility in product selection.

3Market Positioning

Seller's Guide — How to Become a Supplier to HDM Labs Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with HDM Labs Inc, particularly if they can offer products that meet the company's quality standards and align with its strategic focus on diagnostic products and reagents. Diversifying the supplier base could provide HDM Labs Inc with more flexibility and resilience in its supply chain. For Indian exporters, understanding the specific product requirements and quality standards of HDM Labs Inc is crucial to establishing a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply HDM Labs Inc must ensure that their products comply with FDA regulations, including adherence to recognized GMP standards such as EU GMP, WHO GMP, or PIC/S. Products must also meet FDA labeling requirements, including accurate and informative labeling in English. Additionally, exporters should be prepared to provide detailed documentation and undergo inspections as part of the FDA's import process.

3How to Approach

Frequently Asked Questions — HDM Labs Inc

What products does HDM Labs Inc import from India?

HDM Labs Inc imports 2 pharmaceutical products across 1 categories. Top imports: Diagnostic ($550.0K), Reagent ($550.0K).

Who supplies pharmaceuticals to HDM Labs Inc from India?

HDM Labs Inc sources from 2 verified Indian suppliers. The primary supplier is Advy Chemical Private Limited (100.0% of imports, $519.1K).

What is HDM Labs Inc's total pharmaceutical import value?

HDM Labs Inc's total pharmaceutical import value from India is $1.1M, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does HDM Labs Inc focus on?

HDM Labs Inc imports across 1 categories. The largest: Medical Devices & Diagnostics (100.0%).

Get Full HDM Labs Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.